European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 

Discarded surgery fat treats heart attacks 

Stem cells from fat removed during cardiac surgery are cardioprotective

Topics: Basic Science
Date: 04 Jul 2014
Barcelona, 4 July 2014: Stem cells from fat to be discarded during cardiac surgery can improve heart function, according to research that will be presented at Frontiers in CardioVascular Biology (FCVB) 2014 in Barcelona, Spain. The meeting is organised by the Council on Basic Cardiovascular Science of the European Society of Cardiology (ESC) in collaboration with 13 European cardiovascular science societies.

Dr Ganghong Tian, senior author of the study, said: “During cardiac surgery fat tissue may need to be removed from patients to expose the heart. We were intrigued to find out whether this mediastinal fat, which would otherwise be discarded, contained stem cells that could be injected back into the heart before closing the chest. The idea was to improve heart function after a heart attack or heart failure.”

He added: “The advent of liposuction to remove unwanted body fat led to research on stem cells from subcutaneous fat. These cells have been shown to improve cardiac function, reduce myocardial infarct size and increase the regeneration of new blood vessels. But obtaining these from a patient undergoing cardiac surgery requires pre-surgery to collect adipose tissue from the subcutaneous region.”

Dr Tian continued: “The beauty of using mediastinal adipose tissue is that there is no need for another surgical procedure. Our method converts useless tissue into a treatment. Using a patient’s own tissue avoids the possibility of their immune system rejecting the stem cells.”

The current study aimed to discover whether stem cells could be isolated from mediastinal fat tissue, differentiate into distinct cell types, and improve heart function. The researchers collected mediastinal fat tissue removed from 24 patients during cardiac surgery. Stem cells were isolated from the tissue using a standard procedure.

The researchers found that a significant number of stem cells could be isolated from the mediastinal fat tissue. Stem cells from both mediastinal and subcutaneous fat deposits were able to differentiate into adipocytes and osteocytes, and they expressed markers for cardiomyocytes. Dr Tian said: “We have not been able to make the stem cells from either region into beating cardiomyocytes. This is a future goal of our work.”

The ability of stem cells from mediastinal fat tissue to improve heart function was tested in a rat model of congestive heart failure, which was created by occluding the left anterior descending coronary artery. Stem cells were injected into the infarct region of 13 rats while 5 rats received a saline solution as control.

After 6 weeks, MRI showed that mediastinal fat stem cells improved functional recovery of the heart compared to saline. Rats injected with mediastinal fat stem cells had no decrease in left ventricular ejection fraction and a significantly greater ventricular contractility.

Dr Tian said: “This is the first evidence that stem cells collected from the mediastinal fat region are cardioprotective. They displayed the same cardioprotective capacity we found in our previous research on stem cells from subcutaneous fat tissue. This raises the exciting possibility of using a patient’s own stem cells, isolated from waste tissue during cardiac surgery, to improve their heart function.”

He added: “The next stage of our research is to extend the recovery period beyond 6 weeks to see whether these stem cells can provide long-term improvement in cardiac function. We will also work to induce the stem cells into functional cardiomyocytes which exhibit electrical pulsing and contractile function (beating).”

Dr Tian continued: “A technique is also needed to quickly isolate stem cells from the mediastinal fat tissue so that the cells can be injected back into the patient during cardiac surgery. It currently takes several hours to purify the cells and we are looking for collaborators to help us devise a more efficient method.”

He concluded: “Cardiac surgery aims to treat heart failure or restore normal blood flow to the heart. The major strength of our study is that we used waste tissue to isolate the patient’s own stem cells. Injecting these back into the patient while their chest is still open would essentially give them a double treatment during one procedure and improve their chances of recovery from ischaemic heart disease.”

Please note Spanish version is available for this Press Release

Conclusion Did you want to tweet about our congress? - if you do, please use the official #FCVBCongress hashtag! Thank you

Authors: ESC Press Office
Alice Prieto
press@escardio.org
Tel: +336 22 41 84 92
European Society of Cardiology

Notes to editor
About FCVB
Frontiers in CardioVascular Biology (FCVB) is a comprehensive basic science conference organised every two years by the ESC Council on Basic Cardiovascular Science, whose mission is to enhance the importance of basic science to clinical cardiology. FCVB 2014 was organised in collaboration with 13 European cardiovascular science societies.

About the European Society of Cardiology (ESC)
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

  • Information for journalists attending FCVB 2014If you have any question or request regarding interview opportunities, please contact: ESC Press Office - Alice Prieto
  • press@escardio.org
    Tel: +336 22 41 84 92 (off site support number)
  • FCVB 2014 takes place in Barcelona, Spain, on 4 – 6 July 2014 at the Palau de Congressos de Catalunya.  
Please note that this year the ESC Congress 2014 will also take place in Barcelona, at FIRA Gran Via from 30 August – 3 September 2014.

You can already register on-line as press here.


  • Look here for the current programme at a glance
  • For full details of a session, have a look at the Scientific Programme & Planner here.
  • On-site Press registration process:
  • Free registration applies to press representatives upon receipt of valid credentials and a fully completed embargo form.
  • Credential: either your ID press card or letter of assignment with proof of 3 published articles
  • Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives
  • The decision of the ESC Press Office is final regarding all press registration requests.
  • When your registration as press will be validated you will be given a press badge and the press kit.


 
Registration
2014
Frontiers in 
  CardioVascular Biology

  4-6 July, Barcelona
ESC Congress
  30 Aug-3 Sep, Barcelona
Acute Cardiovascular Care
  18-20 Oct, Geneva
EuroEcho-Imaging
  3-6 Dec, Vienna

Receive My ESC News